IL-35在2型糖尿病合并颈动脉粥样硬化病变中的作用

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1171 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the role of IL35 in the pathogenesis of type 2 diabetes mellitus (T2DM) with carotid atherosclerosis (CAS). Methods: A total of 70 patients with T2DM were enrolled，including 36 patients diagnosed with T2DM without CAS, 34 patients diagnosed with T2DM with CAS, and 35 age, gender and body mass index(BMI) matched healthy control group were enrolled. The expression of P35 mRNA and EBI3 mRNA in peripheral blood mononuclear cells(PBMCs) were detected by realtime quantitative PCR. The concentration of serum IL35 and sVCAM1 were measured using multifunction flow type dot matrix instrument Luminex 200. The model of high glucose stimulated human umbilical vein endothelial cells (HUVECs) was established in vitro, then divided into low glucose(LG) conditions(5 mmol/L glucose), high glucose(HG) conditions (25 mmol/L glucose), high mannitol conditions(25 mmol/L mannitol) and IL35+HG (50 ng/mL IL35+25 mmol/L glucose). The apoptosis rate of HUVECs and the positive rate of VCAM1 in each group were detected by Flow cytometry. Results: Compared to those of control group \[(9.37(3.72-14.55 ng/mL)\], the concentration of serum IL35 were lower in the T2DM alone group\[5.01（2.37-9.87）ng/mL\], and much lower in T2DM with CAS group\[3.92(2.15-6.36)ng/mL\] . Compared to those of control group \[687.4（664.2-832.6）\], the concentration of serum sVCAM1 were higher in the simple T2DM group\[785.2（754.5-938.1）\], and much higher in T2DM with CAS group\[932.4（892.6-1 028.3）\]. Compared to those of control group, the expression of P35 mRNA were lower in the T2DM alone group and T2DM with CAS group. the expression of EBI3 mRNA were similar in all three groups (P>0.05). Compared to those of LG group, The apoptosis rate of HUVECs in HG group were higher after treated with 24 h and 48 h (P<0.05). Compared to those of HG group, the apoptosis rate of HUVECs were lower in IL-35+HG group after treated with 48 h. Compared with LG group, the positive rate of VCAM-1 increased in HG group after 48 h (P<0.05). Compared with HG group, the positive rate of VCAM-1 decreased in IL-35+HG group after 48 h (P<0.05). Conclusion: IL-35 may play a protective role in hyperglycemia-induced endothelial cell injury in vivo and in vitro.

Received: 24 April 2018

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2018/V28/I05/431

［1］Zhang J, Liu YY, Sun HL, et al. High human cytomegalovirus IgG level is associated with increased incidence of diabetic atherosclerosis in type 2 diabetes mellitus patients\[J\].Med Sci Monit,2015, 21:4102-4210.

［2］Apro J, Parini P, Broijersén A, et al. Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients\[J\]. J Lipid Res, 2015, 56(8):1633-1639.

［3］Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications\[J\]. Rev Endocr Metab Disord, 2010, 11(1):61-74.

［4］Dixon KO, van der Kooij SW, Vignali DA, et al. Human tolerogenic dendritic cells produce IL35 in the absence of other IL12 family members\[J\]. Eur J Immunol, 2015,45(6):1736-1747.

［5］Li X, Fang P, Yang WY, et al. IL35, as a newly proposed homeostasisassociated molecular pattern, plays three major functions including antiinflammatory initiator, effector, and blocker in cardiovascular diseases\[J\]. Cytokine, 2017, S1043-4666 (17):30169-30172.

［6］中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)\[J\].中华内分泌代谢杂志，2014,30 (10)：447-498

［7］Kotb NA, Gaber R, Salama M, et al. Clinical and biochemical predictors of increased carotid intimamedia thickness in overweight and obese adolescents with type 2 diabetes\[J\]. Diab Vasc Dis Res, 2012, 9(1):35-41.

［8］Sha X,Meng S, Li X,et al. Interleukin35 inhibits endothelial cell activation by suppressing MAPKAP1 pathway\[J\]. J Biol Chem, 2015, 290(31):19307-19318.

［9］Collison LW, Vignali DAA. Interleukin35: odd one out or part of the family?\[J\]. Immunol Rev, 2008, 226 (1) :248-262.

［10］Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL35 contributes to regulatory Tcell function\[J\]. Nature, 2007, 450 (7169) :566-569.

［11］Vignali DA, Kuchroo VK.IL12 family cytokines: immunological playmakers\[J\].Nat Immunol, 2012, 13 (8) :722-726.

［12］Fu H,Tang YY,Ouyang XP,et al. Interleukin27 inhibits foam cell formation by promoting macrophage ABCA1 expression through JAK2/STAT3 pathway\[J\]. Biochem Biophys Res Commun,2014, 452(4):881-887.

［13］Dorosz SA, Ginolhac A, Kahne T, et al. Role of calprotectin as a modulator of the IL27mediated proinflammatory effect on endothelial cells\[J\]. Mediators Inflamm, 2015, 2015 (3) :1-16.

［14］Qiu HN, Liu B, Liu W, et al. Interleukin27 enhances TNFαmediated activation of human coronary artery endothelial cells\[J\]. Mol Cell Biochem,2016, 411(1): 1-10.

［15］Rosalinda PS, Nonanzit PH, José Manuel RP, et al. Interleukin27 polymorphisms are associated with premature coronary artery disease and metabolic parameters in the Mexican population: the genetics of atherosclerotic disease (GEA) Mexican study\[J\]. Oncotarget, 2017,8(38):64459-64470.

［16］Li Y, Wang Y, Liu Y, et al. The possible role of the novel cytokines IL35 and IL37 in inflammatory bowel disease\[J\]. Mediators Inflamm, 2014, 2014 (7):136329-136339.

［17］Cai Z, Wong CK, Kam NW, et al. Aberrant expression of regulatory cytokine IL35 in patients with systemic lupus erythematosus\[J\]. Lupus, 2015, 24 (12):1257-1266.